Stage III head and neck cancer represents a critical point in the disease where timely, well-planned treatment can make a significant difference in outcomes and quality of life. Understanding your treatment options—from standard approaches that have been used for decades to innovative therapies being tested in clinical trials—empowers you to work with your medical team to choose the path that’s right for you.

What Does Stage III Mean and How Does It Shape Treatment Decisions?

When doctors talk about stage III head and neck cancer, they’re describing a situation where the disease has advanced beyond its earliest phases but hasn’t yet spread to distant parts of the body. This stage indicates that the tumor has either grown larger than 4 centimeters, or that it has spread to one nearby lymph node on the same side of the neck as the tumor, with that lymph node measuring no more than 3 centimeters across^[2][4]. The cancer may also have spread to nearby tissues or be affecting a vocal cord in some cases.

Understanding the stage of your cancer is essential because it directly influences the treatment plan your medical team will recommend. The staging process involves careful examination and imaging tests to determine exactly where the cancer is located, how large it has grown, and whether it has reached the lymph nodes^[4]. This information guides doctors in choosing between surgery, radiation therapy, chemotherapy, or combinations of these approaches.

The goal of treatment at this stage is not just to eliminate cancer cells, but also to preserve as much function as possible. Head and neck cancers affect parts of the body that are crucial for speaking, eating, breathing, and facial expression. Treatment teams work hard to balance the need to control the disease with the importance of maintaining quality of life. Many patients with stage III head and neck cancer can be treated successfully, especially when care begins promptly after diagnosis.

Standard Treatment Approaches: The Foundation of Care

For decades, doctors have relied on three main treatment methods for stage III head and neck cancer: surgery, radiation therapy, and chemotherapy. These established treatments form the backbone of cancer care, and medical societies worldwide have developed detailed guidelines for how and when to use them. The specific treatment plan depends on the exact location of the tumor, whether it has reached lymph nodes, and the patient’s overall health.

Surgery is often considered for stage III disease, particularly when the tumor can be completely removed^[10][14]. The surgical procedure, called a laryngopharyngectomy with neck dissection, involves removing part or all of the voice box and throat, along with the affected lymph nodes in the neck. This is a major operation that can significantly affect a person’s ability to speak and swallow. Surgeons often perform reconstructive procedures at the same time to help restore appearance and function. Patients may need a breathing tube (called a tracheostomy) and a feeding tube to help with nutrition during recovery.

Radiation therapy uses high-energy beams to kill cancer cells. For stage III head and neck cancer, doctors typically deliver radiation doses of 66 to 72 Gray over several weeks, with treatments given Monday through Friday^[14][17]. A specialized technique called intensity-modulated radiation therapy, or IMRT, allows doctors to target the tumor more precisely while reducing damage to surrounding healthy tissues like the salivary glands. This can help minimize side effects such as dry mouth, which can be a long-lasting problem after treatment.

Chemoradiation—giving chemotherapy and radiation therapy at the same time—has become the current standard of care for many patients with locally advanced head and neck cancer^[10][14]. The chemotherapy drugs make the cancer cells more sensitive to radiation, improving the treatment’s effectiveness. The most commonly used chemotherapy drug for this purpose is cisplatin, which is given intravenously either as a high dose every three weeks (100 mg/m² on days 1, 22, and 43) or as a lower weekly dose (40 mg/m² weekly for six to seven weeks)^[14].

The duration of treatment varies depending on the approach chosen. Radiation therapy typically continues for about seven weeks. When surgery is part of the plan, radiation therapy usually starts within six weeks after the operation to give the surgical wounds time to heal. Patients who receive both surgery and radiation therapy may face a longer overall treatment timeline, but this combined approach can be necessary for more advanced tumors.

Side effects from standard treatments can be significant and vary depending on which treatments are used. Surgery can affect the ability to speak and swallow, and may require long-term rehabilitation with speech and swallowing therapists. Radiation therapy commonly causes skin irritation in the treatment area, fatigue, mouth sores, difficulty swallowing, and changes in taste. Dry mouth can persist for months or even years after radiation ends. Chemotherapy with cisplatin can cause nausea, vomiting, kidney problems, hearing loss, and numbness or tingling in the hands and feet (called peripheral neuropathy)^[12].

Managing these side effects is a crucial part of cancer care. Patients typically work with a team of specialists including dentists, nutritionists, speech therapists, physical therapists, and social workers to address the challenges that arise during and after treatment^[14]. Pain management, nutritional support through feeding tubes if needed, and rehabilitation services all play important roles in helping patients maintain the best possible quality of life during treatment.

Innovative Treatments in Clinical Trials: The Future of Care

While standard treatments remain the foundation of care, researchers are constantly working to develop new approaches that might work better or cause fewer side effects. Clinical trials give patients access to these cutting-edge treatments before they become widely available. For stage III head and neck cancer, several promising therapies are currently being studied.

Immunotherapy represents one of the most exciting advances in cancer treatment. These drugs work by helping the patient’s own immune system recognize and attack cancer cells. The immune system normally has “checkpoints” that prevent it from attacking the body’s own tissues. Cancer cells can exploit these checkpoints to hide from immune attack. Checkpoint inhibitor drugs block these checkpoints, allowing the immune system to fight the cancer more effectively^[12].

Pembrolizumab (brand name Keytruda) is an immunotherapy drug that targets a checkpoint protein called PD-1. For patients with stage III head and neck cancer, pembrolizumab may be given before surgery to shrink the tumor^[10]. It can then be continued along with radiation therapy, with or without cisplatin chemotherapy, and after radiation therapy finishes. This approach is being studied to see if it can improve outcomes compared to standard treatment alone. Pembrolizumab works by blocking the interaction between PD-1 on immune cells and PD-L1 on cancer cells, essentially removing the “brakes” that prevent the immune system from attacking the tumor.

Another immunotherapy drug, nivolumab, works in a similar way by targeting PD-1. Both pembrolizumab and nivolumab have already been approved for recurrent or metastatic head and neck cancer, and researchers are now studying whether they can help patients with earlier-stage disease like stage III^[12]. These drugs are generally given intravenously every two to three weeks.

Cetuximab is a targeted therapy drug that has been studied for head and neck cancer for many years. Unlike chemotherapy, which attacks all rapidly dividing cells, cetuximab specifically targets the epidermal growth factor receptor, or EGFR—a protein found in high levels on many head and neck cancer cells. By blocking this receptor, cetuximab can slow or stop cancer cell growth. In clinical practice, cetuximab is given along with radiation therapy as an alternative for patients who cannot tolerate cisplatin chemotherapy^[14]. It is given as an initial loading dose of 400 mg/m² one week before radiation starts, followed by weekly doses of 250 mg/m² throughout the radiation treatment period. Patients receive medications before each cetuximab infusion to prevent allergic reactions.

Induction chemotherapy—giving chemotherapy before the main treatment (surgery or chemoradiation)—is another approach being refined in clinical trials^[14]. The idea is to shrink the tumor first, which might make surgery easier or allow some patients to avoid surgery altogether. The most common induction chemotherapy combination uses cisplatin and a drug called fluorouracil (also known as 5-FU). Early results from some studies have shown that tumors can shrink significantly with this approach, potentially leading to better surgical outcomes.

Clinical trials follow a structured process with different phases. Phase I trials test a new treatment in a small group of people to evaluate its safety and identify the best dose. Phase II trials involve more patients and focus on whether the treatment actually works against the cancer—does it shrink tumors or improve survival? Phase III trials compare the new treatment directly with the current standard treatment in large groups of patients to determine if the new approach is better^[12].

Preliminary results from immunotherapy trials have been encouraging. Some studies have shown that adding checkpoint inhibitors to standard treatment can improve response rates and may extend the time before cancer returns. In some trials, patients treated with immunotherapy plus chemoradiation have shown better tumor shrinkage than those receiving chemoradiation alone. The side effect profile of immunotherapy differs from traditional chemotherapy—instead of causing nausea and hair loss, immune checkpoint inhibitors can cause inflammation in various organs including the lungs, intestines, liver, or thyroid gland. These side effects, called immune-related adverse events, usually respond well to treatment with anti-inflammatory medications if caught early.

Clinical trials for head and neck cancer are conducted at major cancer centers throughout the United States, Europe, and other regions. Patients interested in clinical trials should discuss this option with their oncologist. Eligibility for trials depends on many factors including the exact location and characteristics of the cancer, whether it has been treated before, and the patient’s overall health. Insurance coverage for clinical trials varies, but many insurance plans cover the standard care portions of trial participation.

Most common treatment methods

• Surgery
  • Laryngopharyngectomy with neck dissection removes part or all of the voice box and throat along with affected lymph nodes^[10]
  • Tracheostomy placement to help with breathing during recovery
  • Feeding tube placement (gastrostomy) to ensure adequate nutrition
  • Reconstructive surgery performed at the same time to restore appearance and function
• Radiation Therapy
  • External beam radiation delivered in doses of 66-72 Gray over approximately seven weeks^[14][17]
  • Intensity-modulated radiation therapy (IMRT) allows precise targeting while protecting healthy tissues^[10]
  • Postoperative radiation therapy given within six weeks after surgery when needed^[14]
• Chemotherapy
  • Cisplatin given concurrently with radiation therapy, either as high-dose every three weeks (100 mg/m²) or weekly low-dose (40 mg/m²)^[14]
  • Induction chemotherapy with cisplatin and fluorouracil given before main treatment to shrink tumors^[10]
• Chemoradiation
  • Combination of chemotherapy and radiation therapy given simultaneously for enhanced effectiveness^[10][14]
  • Considered the current standard of care for many patients with locally advanced head and neck cancer
• Targeted Therapy
  • Cetuximab targets the epidermal growth factor receptor (EGFR) on cancer cells^[14]
  • Given as 400 mg/m² loading dose before radiation starts, then 250 mg/m² weekly during radiation
  • Used as an alternative for patients who cannot tolerate cisplatin
• Immunotherapy
  • Pembrolizumab (Keytruda) blocks PD-1 checkpoint protein to activate immune response against cancer^[10][12]
  • May be given before surgery, with radiation therapy, and as maintenance treatment
  • Nivolumab works similarly by targeting PD-1 checkpoints